Form 4: Xilio Therapeutics Director Receives Stock Option Grant

Director James Samuel Shannon was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Director James Samuel Shannon received a grant of 5,000 stock options for Xilio Therapeutics, Inc. (XLO) common stock.
• The options have an exercise price of $7.99 per share.
• The grant date is June 11, 2026, with an expiration date of June 10, 2036.
• The options are set to vest 100% on the earlier of June 11, 2027, or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of XLO common stock exceeding the $7.99 exercise price.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and strategic alignment in the biotechnology sector.

Comparison to Industry Standards

• The grant of 5,000 options is consistent with typical non-employee director compensation packages for small-cap biotechnology firms.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 11, 2027, or the next annual meeting.

Key Dates

Keywords

Xilio Therapeutics, XLO, Form 4, Insider Trading, Stock Options, Director Compensation